Investigation Report on China’s Insulin Detemir Market, 2018-2022 - ResearchAndMarkets.com

January 2, 2019

DUBLIN--(BUSINESS WIRE)--Jan 2, 2019--The “Investigation Report on China’s Insulin Detemir Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

In the past three decades, the incidence of diabetes kept rising in China with the aging population, changed dietary habits and reduced physical activities resulting from rapid economic development.

It is estimated that at the end of 2017, there were more than 100 million diabetic patients in China. Most of them are Type 2 diabetic patients. The increasing number of diabetic patients expands the market size of diabetes drugs in China.

Developed by Danish company Novo Nordisk with genetically engineered recombinant human insulin, Insulin Detemir is a new-type long-acting soluble insulin analog that avoids the common side effects of non-soluble insulin.

In 2005, Novo Nordisk’s Insulin Detemir (trade name: Levemir) was launched in the U.S. In 2014, the global sales value of Levemir reached USD 2 billion. In 2017, it was USD 2.28 billion, about 17.7% lower than that in 2016.

This market research shows that since 2009 when the drug was introduced to China, the sales value of Insulin Detemir has been rising. It increased from less than CNY 3 million in 2010 to more than CNY 100 million in 2017.


According to this report, by the end of 2018, China’s Insulin Detemir will be monopolized by Novo Nordisk. However, some Chinese companies are developing generic Insulin Detemir.

For example, Tonghua Dongbao Pharmaceutical Co., Ltd. filed the CFDA with the drug registration applications for Insulin Detemir API and Insulin Detemir injection on Apr. 15, 2015, and obtained the clinical trial approvals for its Insulin Detemir API and Insulin Detemir injection on Oct. 20, 2017.

Other companies have also applied for registering their Insulin Detemir API and Insulin Detemir injections but have not obtained the approvals yet. These companies include Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Zhuhai United Laboratories Co., Ltd. From 2020, the generic Insulin Detemir by Chinese pharmaceutical companies will be launched in succession.

It is expected that as the number of diabetic patients continues to grow, Insulin Detemir will still have huge market potential from 2018 to 2022.

Topics Covered

Situation of diabetes in China Sales of Insulin Detemir in China Prices of Insulin Detemir in China Progress of generic Insulin Detemir by Chinese enterprises Prospect of China’s Insulin Detemir market from 2018 to 2022

List of Chapters

1 Relevant Concepts of Insulin Detemir

2 Sales of Insulin Detemir in China, 2013-2017

3 Analysis on Major Insulin Detemir Manufacturers in China, 2013-2017

4 Prices of Insulin Detemir in China, 2017-2018

5 Prospect of China’s Insulin Detemir Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/2hpcj9/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005275/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs,Diabetes Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/02/2019 07:21 AM/DISC: 01/02/2019 07:21 AM


Update hourly